Drug Profile
Research programme: anthrax therapy - Advanced Biosystems
Alternative Names: Anthrax therapy research programme - Advanced BiosystemsLatest Information Update: 13 Oct 2006
Price :
$50
*
At a glance
- Originator Advanced Biosystems
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 01 Jun 2006 No development reported - Preclinical for Anthrax in USA (unspecified route)
- 05 Jul 2002 Hadron is now called Alanex Corporation
- 27 Jun 2001 Preclinical development for Anthrax in USA (Unknown route)